Nested Therapeutics Presents First Preclinical Data for Lead Candidate, NST-628, a RAS/MAPK Pathway Inhibitor at 2023 AACR-NCI-EORTC Conference

Posted on by

NST-628 demonstrates superior anti-cancer activity in animal models for multiple tumor types and potential for daily dosing NST-628 broadly penetrates the CNS in animal models NST-628 robustly and durably decreases RAS/MAPK pathway reactivation IND filing expected in first half of 2024…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.